China National Accord Medicines Corp Ltd (200028) — Cash Flow Quality Index
China National Accord Medicines Corp Ltd (200028) has a Cash Flow Quality Index of -1.46x as of September 2025. Operating cash flow of HK$-424.00 Million is below net income of HK$291.12 Million, suggesting accrual-heavy earnings not yet converted to cash. Explore investment intensity of China National Accord Medicines Corp Ltd to see how much of total assets are deployed in long-term investments.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
China National Accord Medicines Corp Ltd Cash Flow Quality Index (1998–2025)
Historical Cash Flow Quality Index for China National Accord Medicines Corp Ltd across 27 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check how tangible is China National Accord Medicines Corp Ltd's equity to evaluate the tangible quality of the company's equity base.
Annual Cash Flow Quality Index for China National Accord Medicines Corp Ltd (1998–2025)
Year-by-year earnings quality comparison for China National Accord Medicines Corp Ltd. For live market cap and the full company financial profile, see China National Accord Medicines Corp Ltd (200028) market capitalisation.
| Year | Quality Index | Operating CF (HKD) | Net Income | YoY Change |
|---|---|---|---|---|
| 2025 | 1.44x | HK$1.64 Billion | HK$1.14 Billion | ▼ -89.5% |
| 2024 | 13.80x | HK$3.27 Billion | HK$237.00 Million | ▲ +820.4% |
| 2023 | 1.50x | HK$2.94 Billion | HK$1.96 Billion | ▲ +3.8% |
| 2022 | 1.45x | HK$2.56 Billion | HK$1.77 Billion | ▲ +33.4% |
| 2021 | 1.08x | HK$1.66 Billion | HK$1.53 Billion | ▲ +24.1% |
| 2020 | 0.87x | HK$1.50 Billion | HK$1.72 Billion | ▼ -35.2% |
| 2019 | 1.35x | HK$2.00 Billion | HK$1.48 Billion | ▲ +37.4% |
| 2018 | 0.98x | HK$1.32 Billion | HK$1.35 Billion | ▼ -11.7% |
| 2017 | 1.11x | HK$1.29 Billion | HK$1.16 Billion | ▼ -3.3% |
| 2016 | 1.15x | HK$1.47 Billion | HK$1.28 Billion | ▼ -13.7% |
| 2015 | 1.33x | HK$1.05 Billion | HK$787.35 Million | ▲ +211.9% |
| 2014 | -1.19x | HK$-796.70 Million | HK$669.84 Million | ▼ -236.6% |
| 2013 | 0.87x | HK$465.03 Million | HK$534.22 Million | ▲ +30.0% |
| 2012 | 0.67x | HK$323.96 Million | HK$483.68 Million | ▼ -3.4% |
| 2011 | 0.69x | HK$227.32 Million | HK$327.82 Million | ▼ -57.2% |
| 2010 | 1.62x | HK$428.16 Million | HK$264.22 Million | ▲ +18.6% |
| 2009 | 1.37x | HK$270.85 Million | HK$198.26 Million | ▼ -10.0% |
| 2008 | 1.52x | HK$246.58 Million | HK$162.45 Million | ▲ +116.2% |
| 2007 | 0.70x | HK$87.70 Million | HK$124.91 Million | ▼ -70.0% |
| 2006 | 2.34x | HK$181.73 Million | HK$77.76 Million | ▼ -43.6% |
| 2005 | 4.15x | HK$148.28 Million | HK$35.77 Million | ▼ -15.4% |
| 2004 | 4.90x | HK$130.30 Million | HK$26.58 Million | ▼ -8.9% |
| 2003 | 5.38x | HK$81.22 Million | HK$15.11 Million | ▼ -20.1% |
| 2002 | 6.73x | HK$28.76 Million | HK$4.28 Million | ▲ +227.3% |
| 2001 | 2.06x | HK$71.16 Million | HK$34.61 Million | ▲ +130.7% |
| 1999 | 0.89x | HK$22.84 Million | HK$25.62 Million | ▲ +141.6% |
| 1998 | 0.37x | HK$5.21 Million | HK$14.12 Million | — |